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ABSTRACT
Background. Fentanyl buccal tablet (FBT; FENTORA
®, Cephalon, Inc., Frazer, PA, USA) is indicated in the US for
breakthrough pain in patients with cancer who are already receiving and are tolerant to around-the-clock opioid
therapy for underlying persistent cancer pain. For each individual patient, FBT should be titrated to the effective
dose.
Objective. The primary objective was to characterize the pharmacokinetic parameters of FBT 400 mg administered
as a single 400 mg tablet (regimen A) or as two 200 mg tablets given simultaneously (regimen B) and determine
whether these are bioequivalent in healthy Japanese volunteers. Regimen C (two 200 mg tablets 30 minutes apart) was
also compared as a secondary objective.
Methods. Healthy Japanese adults received regimens A, B, and C in a crossover fashion. Naltrexone was given to
minimize the opioid effects of fentanyl. Serum fentanyl concentrations were determined in venous blood collected
through 36 hours post dose. Regimens were declared bioequivalent with respect to bioavailability (as reﬂected by
AUC0–•, AUC0–last, and Cmax) if the 90% conﬁdence interval (CI) of the regimens’ ratio fell within 0.80–1.25
(80%–125%).
Results. Twenty-nine volunteers (13 men, 16 women) were enrolled; 24 completed the study. Regimens A and B had
bioequivalent systemic exposure parameters (B/A [90% CI]: AUC0–• 108.4 [103.4, 113.7], AUC0–last 106.1 [100.7,
111.7], and Cmax 92.3 [83.2, 102.4]). Regimen C was bioequivalent to both A and B for AUCs, but only to B for Cmax.
Median time to Cmax was 45 minutes for regimen A and 60 minutes for regimens B and C. The most frequent AEs
were dizziness, application-site erythema, headache, somnolence, nausea, and vomiting. All AEs were mild or
moderate.
Conclusions. Bioavailability of fentanyl after FBT 400 mg administered as a single tablet was bioequivalent to that
after 2 simultaneously administered 200 mg tablets in healthy Japanese volunteers. AEs were mild or moderate.
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Introduction
F
entanyl buccal tablet (FBT; FENTORA
®,
Cephalon, Inc., Frazer, PA, USA) is a novel
formulation of fentanyl that uses OraVescent
®
technology (CIMA LABS, INC., Eden Prairie,
MN, USA) to enhance the rate and extent of fen-
tanyl absorption across the buccal mucosa [1].
FBT has been shown to provide onset of analgesia
in 10 minutes and is indicated for the management
of breakthrough pain in patients with cancer who
are already receiving and are tolerant to around- This study was sponsored by Cephalon, Inc., Frazer, PA.
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cancer pain [2–4].
FBT is available in doses of 100, 200, 300, 400,
600, and 800 mg, and it should be titrated to the
effective dose for each individual patient. To facili-
tate titration, it would help to understand the rela-
tive bioavailability achieved with multiple tablets
of a low dose compared with that achieved with a
single tablet of a higher dose. This information
may allow the patient to switch from multiple low-
dose tablets to a single higher-dose tablet if
necessary [5].
This study was conducted to support the sub-
mission of a new drug application for FBT in
Japan. The primary objective of the study was to
characterize the pharmacokinetic parameters of
FBT 400 mg administered as a single 400 mg tablet
(regimen A) or as two 200 mg tablets administered
simultaneously (regimen B) and to determine
whether these 2 regimens provide bioequivalent
bioavailability (as reﬂected by parameters measur-
ing systemic exposure) in healthy Japanese volun-
teers. Secondary objectives included evaluation of
the pharmacokinetic parameters of FBT 400 mg
administered as two 200 mg tablets given 30
minutes apart (regimen C) and comparison of the
results with those obtained with regimens A and B.
Methods
Study Population
Healthy Japanese men and women residing in the
United States who were aged 20 to 55 years, had
lived fewer than 10 years outside of Japan, and had
a body mass index of 17.6 to 29 kg/m
2 were eligible
for the study. Inclusion criteria included clinically
normal ﬁndings on physical examination and from
medical history (no cardiovascular, pulmonary,
hepatic, renal, hematologic, gastrointestinal, end-
ocrine, immunologic, dermatologic, neurologic,
or psychiatric disease). Results from laboratory
tests and electrocardiography were required to be
within normal ranges.
Prior to the ﬁrst dose of study drug, volunteers
were not to have taken the following agents: pre-
scription medications (except for oral contracep-
tion for women) within 14 days, over-the-counter
medication and herbal supplements within 7 days,
strong inhibitors of cytochrome P450 (CYP)
enzymes within 10 days, and strong inducers of
CYP enzymes within 30 days. These agents were
not allowed during the study.
Volunteers were excluded if they had smoked
more than 10 cigarettes per day during the 3
months prior to the ﬁrst dose of FBT. Tobacco use
was limited to 10 cigarettes during the washout
phases. Women who were pregnant or lactating
were excluded from the study.
Study Design
This open-label, randomized, 3-phase crossover
study was conducted at a single center (Radiant
Research, Honolulu, HI). Aspire Institutional
Review Board approved the study protocol. All
volunteers provided written informed consent.
Volunteers were randomly assigned to receive
FBT 400 mg as a single-dose tablet (regimen A),
two 200 mg tablets administered simultaneously
(regimen B), and two 200 mg tablets administered
30 minutes apart (regimen C) in a crossover design
with a 7-day washout between regimens. For regi-
mens B and C, 1 tablet was placed on each side of
the mouth. To minimize carryover effects, regi-
mens were allocated using a Latin square design.
Because healthy volunteers are not opioid tolerant,
naltrexone was given during each regimen to mini-
mize the opioid effects of fentanyl; they received 1
naltrexone 50 mg tablet 15 hours and 3 hours
before and 12 hours after FBT placement. Coad-
ministration of naltrexone with fentanyl would not
be expected to affect the pharmacokinetics of fen-
tanyl because fentanyl is a substrate of CYP3A4
[6], and naltrexone is not an inhibitor or inducer of
CYP3A4 [7].
Volunteers self-administered FBT by placing it
above a molar tooth (i.e., buccally) and allowing it
to dissolve for 10 minutes. If any portion of the
tablet remained, volunteers were instructed to
gently massage the adjacent cheek area for 5
minutes to facilitate dissolution. Any tablet residue
remaining at this time (veriﬁed by study center
personnel) was allowed to dissolve on its own
(further massaging of the cheek area by the subject
was allowed, if needed). FBT was administered at
the same time of day in each study phase.
DwellTime Assessment
Dwell time, deﬁned as the time from tablet place-
ment to complete disappearance of any tablet
residue (veriﬁed visually), was recorded by study
personnel.
Sample Collection
Venous blood was collected immediately before
and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, and 55
minutes, and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10,
12, 16, 20, 24, 28, 32, and 36 hours after FBT
placement. Blood samples were allowed to clot at
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centrifugation at 2,500 revolutions per minute for
15 minutes at 4°C, then stored in polypropylene
containers at or below -20°C until assayed.
Analytical Methods
Serum fentanyl concentrations were quantiﬁed
using a validated assay for high performance liquid
chromatography-mass spectrometry/mass spec-
trometry (HPLC-MS/MS; PE SciEx API 3000,
API 4000, API 365, and API III Plus with an ESI
interface). The analyte and internal standard (d5-
fentanyl) were isolated by liquid-liquid extraction
under basic conditions. Serum extracts were
evaporated to dryness and reconstituted for injec-
tion onto the HPLC-MS/MS. Detection was
accomplished using multiple-reaction monitoring
in positive ion mode. The assay was linear from
10 pg/mL to 5,000 pg/mL (0.01 to 5.0 ng/mL),
with a lower limit of quantitation of 50 pg/mL
(0.05 ng/mL). Serum concentrations below the
limit of quantitation were assigned a value of zero.
Quality control samples had an interbatch preci-
sion (% coefﬁcient of variation) of 3.6% and an
interbatch accuracy (% bias) ranging from 100.3%
to 101.3%.
Pharmacokinetic Analysis
The pharmacokinetic parameters determined
included maximum serum fentanyl concentration
(Cmax), time to Cmax (tmax), area under the serum
fentanyl concentration-time curve (AUC) from
time zero (t0) to the time of the last quantiﬁable
serum concentration (tlast) (AUC0–last), AUC from
t0 extrapolated to inﬁnity (AUC0–•), the terminal
elimination phase rate constant (lz), and the elimi-
nation half-life (t 1
2). AUC0–last was obtained by
linear trapezoidal summation from t0 to tlast, and
AUC0–• was obtained as (AUC0–last + Clast/lz),
where Clast was the last quantiﬁable serum fentanyl
concentration. The lz and t 1
2values were obtained
from linear regression of the terminal portion of
the log concentration-versus-time curve. The
pharmacokinetic parameters obtained were used
to compare regimens A and B, B and C, and A and
C. Pharmacokinetic analysis was performed using
standard noncompartmental methods with Win-
Nonlin
® Professional software Version 4.1 or
higher (Pharsight Corp., Mountain View, CA).
Safety andTolerability Assessments
Clinical laboratory tests, a physical examination
with vital signs, and 12-lead electrocardiography
were performed at the screening visit and on
completion of the study or at the time of early
termination. Serial vital signs were recorded
through 36 hours following each study drug
administration, and continuous pulse oximetry was
performed for the ﬁrst 4 hours post dose, as well as
any time the volunteers attempted to sleep when
they were in the clinic. Adverse events (AEs),
including any uncomfortable or unpleasant sensa-
tions in the mouth, were recorded. Study person-
nel examined the oral mucosa at the site of tablet
placement 1 hour after FBT administration (in the
case of regimen C, after the second tablet).
Statistical Analyses
A sample size of 22 volunteers was anticipated to
provide 90% power to reject the null hypothesis of
nonbioequivalence between regimens A and B
using the 2 one-sided tests procedure at the 0.05
level. An analysis of variance model was performed
on the log-transformed values for Cmax, AUC0–•,
and AUC0–last, with ﬁxed effects for regimen,
phase, and regimen order, and subject nested
within regimen order as a random effect. The 90%
conﬁdence interval (CI) for the difference in the
regimens’ least square geometric means from this
model was then exponentiated to yield a 90% CI
for the ratio of the regimens’ least square geomet-
ric means. Bioequivalence was concluded if the
90% CIs of the ratios of the regimens’ least square
geometric means for AUC0–•, AUC0–last, and Cmax
fell within the interval of 0.80 to 1.25 (80%–
125%).
Pharmacokinetic, safety, and tolerability param-
eters were summarized using descriptive statistics;
tests were 2-sided with an a level of 0.05. Wil-
coxon signed rank testing was used to analyze tmax.
The evaluable analysis set comprised the ran-
domized volunteers who completed at least 2
periods of the study; this set was used for the
analysis of bioequivalence. The pharmacokinetic
analysis set comprised the randomized volunteers
who received at least 1 dose of FBT and had suf-
ﬁcient serum fentanyl concentration data to allow
calculation of at least 1 pharmacokinetic param-
eter. The safety analysis set comprised the ran-
domized volunteers who received at least 1 dose of
FBT; the safety analysis set was used for popula-
tion summaries, unless otherwise noted.
Results
Study Population
Twenty-nine Japanese volunteers (13 men, 16
women) aged 20 to 50 years were enrolled in the
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the safety and pharmacokinetic populations. The
evaluable population for the bioequivalence analy-
ses comprised 26 patients. Twenty-seven volun-
teers completed regimens A and B, and 26
completed regimen C. Twenty-four volunteers
completed the study; 2 were discontinued because
of AEs and 3 others withdrew their consent to
participate.
Pharmacokinetic Parameters
The concentration-time proﬁles for fentanyl are
shown in Figure 1. After placement of FBT, regi-
mens A, B, and C were characterized by a rapid
absorption phase followed by a triexponential
decline from peak concentration. Pharmacokinetic
parameters are listed in Table 2. Median tmax was
45 minutes for regimen A and 60 minutes for
regimens B and C (Table 2).
The AUC0–last and AUC0–• values were
bioequivalent between regimens A and B, regi-
mens B and C, and regimens A and C because the
90% CIs for the regimens’ ratios were contained
entirely within the predeﬁned limits of 0.80 to
1.25 (Table 3). The Cmax values were bioequivalent
between regimens A and B and between regimens
B and C. Regimens A and C did not show a
bioequivalent Cmax because the lower limit of the
90% CI of the ratio was marginally outside the
predeﬁned lower limit allowed by the protocol
(Table 3).
Buccal DwellTime
The mean dwell time of FBT in the buccal cavity
was 51.41 minutes following regimen A (range
12–110 minutes), 67.96 minutes following
Figure 1 Mean serum fentanyl con-
centrations after fentanyl buccal tablet
administration delivered as one
400 mg tablet (regimen A), two 200 mg
tablets simultaneously (regimen B), or
two 200 mg tablets administered 30
minutes apart (regimen C). Inset is an
expanded view of the ﬁrst 8 hours
after drug administration.
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Table 1 Demographic variables
N = 29
Age, year (mean [SD]) 32 (8)
Sex, female (N [%]) 16 (55.2)
Weight, kg (mean [SD]) 60.4 (11.4)
Height, cm (mean [SD]) 165.2 (11.4)
Body mass index, kg/m
2 (mean [SD]) 22.0 (2.6)
SD = standard deviation.
Table 2 Pharmacokinetic parameters of fentanyl following various dosing regimens for 400 mg of fentanyl buccal tablet
Parameter
Regimen, mean (SD)
A: One 400 mg tablet
B: Two 200 mg tablets
simultaneously
C: Two 200 mg tablets
30 minutes apart
(N = 27) (N = 27) (N = 26)
Cmax (ng/mL) 2.18 (0.60) 2.05 (0.70) 1.89 (0.54)
tmax* (min) 45 (20, 105) 60 (25, 182) 60 (45, 150)
AUC0–• (ng·h/mL) 8.54 (2.29) 8.91
† (2.17) 8.97 (2.25)
AUC0–last (ng·h/mL) 7.88 (2.13) 8.16 (1.94) 8.29 (2.06)
lz (1/h) 0.11 (0.05) 0.10
† (0.05) 0.10 (0.03)
t 1
2 (h) 7.63 (3.52) 8.55
† (3.47) 7.71 (2.55)
*Data presented as median (range).
†N = 26.
AUC0–• = area under the serum fentanyl concentration-time curve (AUC) from time zero extrapolated to inﬁnity;AUC0–last = AUC0 to the time of the last quantiﬁable
serum fentanyl concentration; Cmax = maximum serum fentanyl concentration; lz = terminal elimination phase rate constant; tmax = time to Cmax; t 1
2 = elimination
half-life.
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following placement of the ﬁrst tablet in regimen
C (range 12–118 minutes), and 64.12 minutes fol-
lowing placement of the second tablet in regimen
C (range 13–151 minutes).
Safety andTolerability
As stated previously, naltrexone was administered
to these healthy volunteers to minimize the
opioid effects of fentanyl. Twenty-three volun-
teers (79.3%) had at least 1 AE, with all AEs
reported as mild or moderate. No serious AEs
occurred during the study. Two volunteers were
discontinued from the study because of AEs that
occurred after administration of the ﬁrst dose of
naltrexone: one because of nausea and vomiting,
and another because of vomiting and dizziness. In
both cases, the AEs occurred prior to receipt of
FBT and were considered by the investigator not
to be related to FBT.
Table 4 displays the most common AEs for each
dosing regimen. Application-site AEs, all of which
were mild, occurred after administration of the
200 mg tablets (regimens B and C), but not after
administration of the 400 mg tablet (regimen A).
There were no clinically relevant changes in vital
signs or electrocardiographic measurements. One
volunteer had a newly diagnosed ﬁnding (rash) at
the end-of-study physical examination that was
considered by the investigator to be mild and not
related to study drug. Laboratory abnormalities
considered clinically signiﬁcant were reported for
1 volunteer (hyperglycemia and glucosuria) who
had the measurements taken approximately 2 to 3
hours after dinner (postprandial).
Discussion
The primary purpose of this study was to evalu-
ate the pharmacokinetic parameters and the rela-
tive bioavailability of FBT administered as a
single 400 mg tablet (regimen A) and as two
200 mg tablets administered simultaneously
(regimen B) in healthy Japanese volunteers who
were administered naltrexone to minimize
opioid-receptor–mediated effects of fentanyl.
Table 3 Statistical analysis for bioequivalence following various fentanyl buccal tablet 400 mg dosing regimens
Parameter Regimen*
Mean
† Ratio over A Ratio over B
(N = 26) % (90% CI) % (90% CI)
AUC0–• (ng·h/mL) A 8.241 — —
B 8.937 108.4 (103.4, 113.7) —
C 8.790 106.7 (101.7, 111.8) 98.4 (93.9, 103.1)
AUC0–last (ng·h/mL) A 7.620 — —
B 8.083 106.1 (100.7, 111.7) —
C 8.123 106.6 (101.2, 112.2) 100.5 (95.5, 105.7)
Cmax (ng/mL) A 2.146 — —
B 1.981 92.3 (83.2, 102.4) —
C 1.833 85.4 (77.0, 94.7) 92.5 (83.6, 102.5)
*Fentanyl buccal tablet study regimens: regimen A = one 400 mg tablet; regimen B = two 200 mg tablets administered simultaneously; regimen C = two 200 mg
tablets administered 30 minutes apart.
†Values for AUC and Cmax are least squares geometric means.
AUC0–• = area under the serum fentanyl concentration-time curve (AUC) from time zero extrapolated to inﬁnity;AUC0–last = AUC0 to the time of the last quantiﬁable
serum fentanyl concentration; CI = conﬁdence interval; Cmax = maximum serum fentanyl concentration.
Table 4 Adverse events occurring in 5% of volunteers in any one of various fentanyl buccal tablet 400 mg dosing
regimens*
Adverse event
Regimen A: One 400 mg
tablet
Regimen B: Two 200 mg
tablets simultaneously
Regimen C: Two 200 mg
tablets 30 minutes apart Total
(N = 27) (N = 27) (N = 26) (N = 29)
N (%) N (%) N (%) N (%)
Application-site AEs
Erythema 0 4 (14.8) 4 (15.4) 7 (24.1)
Ulcer 0 0 2 (7.7) 2 (6.9)
Dizziness 2 (7.4) 5 (18.5) 2 (7.7) 8 (27.6)
Headache 3 (11.1) 3 (11.1) 2 (7.7) 6 (20.7)
Nausea 0 3 (11.1) 2 (7.7) 5 (17.2)
Somnolence 4 (14.8) 5 (18.5) 3 (11.5) 6 (20.7)
Vomiting 0 1 (3.7) 2 (7.7) 3 (10.3)
*Volunteers who had multiple episodes of a given adverse event were counted once.
60 Darwish et al.
Arch Drug Info 2008;1:56–62Systemic exposure to fentanyl, reﬂected by
AUC0–•, AUC0–last, and Cmax, was bioequivalent
with these 2 dosing regimens. Systemic exposure
(AUC0–•, AUC0–last, and Cmax) was also bioequiva-
lent with 2 FBT 200 mg tablets administered
simultaneously (regimen B) and 2 FBT 200 mg
tablets administered 30 minutes apart (regimen
C). FBT administered as a single 400 mg tablet
and as two 200 mg tablets administered 30
minutes apart was bioequivalent with respect to
AUC0–• and AUC0–last, but not with respect to
Cmax, which was lower because volunteers waited
30 minutes to administer the second 200 mg dose
in regimen C. Median tmax values ranged from 45
to 60 minutes among the 3 regimens.
The mean dwell times of FBT in the buccal
cavity ranged from 50.8 to 68.0 minutes. It has
already been shown that the pharmacokinetic
proﬁle of fentanyl delivered by FBT is not affected
by variations in the dwell time of FBT [8].
All AEs were mild or moderate and no serious
AEs occurred. The AE proﬁle was similar to that
found in previously published studies of opioid-
naivevolunteerswhowereadministerednaltrexone
[5,9–12]. It should be noted that interpretation of
the non–application-site AEs is difﬁcult because of
the concomitant administration of naltrexone. The
incidence of application-site AEs suggests that oral
mucosal changes were more frequent with the use
of 2 FBT 200 mg tablets than with a single FBT
400 mg tablet, perhaps because of the additional
mucosal exposure.
One must use caution in applying the results
of this study to the clinical setting. Healthy vol-
unteers are not representative of patients with
breakthrough pain. The presence of comorbid
conditions, such as hepatic or renal failure, may
inﬂuence the concentrations of fentanyl achieved.
Furthermore, the volunteers in this study were
administered naltrexone to minimize the opioid
effects of fentanyl. Thus, the safety and tolerabil-
ity results may not be generalized to a patient
population.
In conclusion, in healthy Japanese volunteers,
systemic exposure to fentanyl was bioequivalent
with 2 FBT 200 mg tablets administered simulta-
neously and a single FBT 400 mg tablet. AEs were
mild or moderate.
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